<?xml version='1.0' encoding='utf-8'?>
<document id="15898679"><sentence text="[The selection of a drug in a defined therapeutic class: the case of the HMG-CoA reductase inhibitors]." /><sentence text="The HMG-CoA reductase inhibitors have similar therapeutic targets and indications" /><sentence text=" However, their potential pharmacokinetic drug-drug interaction profile may play a significant role in their safety profile in polymedicated and polymorbid patients and can serve as a selection criterion" /><sentence text=" If their utility is clearly demonstrated in selected conditions, their safety profile remains of concern" /><sentence text=" Beside dose-related hepatic and muscular injury, other rare and important adverse drug reactions have been reported after prolonged administration such as polyneuropathy, fibrotic interstitial pulmonary disease and lupus-like syndrome" /><sentence text=" Teratogenicity has also been associated with statin therapy" /><sentence text="" /></document>